Page 155 - 2019_08-Haematologica-web

Once- vs. Twice-Weekly Carfilzomib in NDMM
In conclusion, a once-weekly 70 mg/m2 infusion of carfilzomib was shown to be as safe and effective as a twice weekly 36 mg/m2 infusion for the initial treatment of elderly transplant-ineligible NDMM patients, both as induction therapy in combination with cyclophos- phamide and dexamethasone and as single-agent mainte- nance. This analysis supports the use of high-dose once- weekly carfilzomib and provides the rationale for the investigation of once- versus twice-weekly carfilzomib as initial treatment for MM patients.
Funding
The IST-CAR-561 (NCT01857115) study was sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON, the Netherlands), in collaboration with Fondazione
Neoplasie Sangue ONLUS (Italy). The IST-CAR-506 (NCT01346787) study was sponsored by the HOVON Foundation and co-sponsored by Fondazione Neoplasie Sangue ONLUS. Both trials were supported by funding from AMGEN (Onyx Pharmaceuticals), which had no role in study design, data collection, data analysis, data interpretation, writing of the report or publication of this article. The corresponding author had full access to all the data in the two studies and had final responsi- bility for the decision to prepare and submit this manuscript for publication, together with the other authors.
Acknowledgments
We thank the patients who participated in these studies and their families; the study co-investigators, nurses, and coordinators at each of the clinical sites.
References
1. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in mul- tiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128.
2. San Miguel JF, Schlag R, Khuageva NK, et al. Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. J Clin Oncol. 2013;31(4):448- 455.
3. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly borte- zomib in multiple myeloma patients. Blood. 2010;116(23):4745-4753.
4. Dytfeld D, Jasielec J, Griffith KA, et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014;99(9):e162-164.
5. Facon T, Lee JH, Moreau P, et al. Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). Clin Lymphoma Myeloma Leuk. 2017;17(1):e26-e27.
6. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dex- amethasone in patients with newly diag- nosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69.
7. Bringhen S, D’Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018;32(4):979-985.
8. Berenson JR, Cartmell A, Bessudo A, et al.
CHAMPION-1: a phase 1/2 study of once- weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127(26):3360-3368.
9. Moreau P, Mateos M-V, Berenson JR, et al. Once weekly versus twice weekly carfil- zomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018; 19(7):953-964.
10. National Cancer Institute [USA]. Common Terminology Criteria for Adverse Events (CTCAE) Version. 4.0. US Department of Health and Human Services. May 28, 2009.
11. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high- risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.
12. Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report. Blood. 2015;125(13):2068-2074.
13. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexam- ethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
14. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in com- bination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012; 120(9):1801-1809.
15. Gay F, Rota Scalabrini D, Belotti A, et al. Updated efficacy and MRD data according to risk-status in newly diagnosed myeloma patients treated with carfilzomib plus lenalidomide or cyclosphosphamide: Results from the FORTE trial. HemaSphere 2018;2(S1):6. [Abstract #S109, EHA 2018
23rd Congress].
16. GayF,FoàR,MustoP,etal.Updatedeffica-
cy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial). J Clin Oncol. 2018;36(15_suppl) [Abstract #8009, ASCO 2018 Annual Meeting].
17. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multi- ple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38.
18. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or borte- zomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, ran- domised, phase 3 trial. Lancet Oncol. 2017;18(10):1327-1337.
19. Boccia RV, Bessudo A, Agajanian R, et al. A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION- 2). Clin Lymphoma Myeloma Leuk. 2017; 17(7):433-437.
20. Sonneveld P, Asselbergs E, Zweegman S, et al. Phase 2 study of carfilzomib, thalido- mide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2015; 125(3):449-456.
21. Chng W-J, Goldschmidt H, Dimopoulos MA, et al. Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenet- ic risk in the phase 3 study ENDEAVOR. Leukemia. 2017;31(6):1368-1374.
haematologica | 2019; 104(8)
1647